Observational study demonstrates improved survival outcomes in MDS with pre-transplant risk stratification, indicating the potential of dynamic prognostic tools.
Key Points
The research aims to evaluate the prognostic impact of pre-transplant IPSS-M risk downstaging in patients with myelodysplastic syndromes (MDS).
Identified 130 myeloid neoplasm patients at Karmanos Cancer Institute from 1300 records.
Risk stratification utilized the IPSS-M model.
Survival outcomes analyzed using Kaplan-Meier curves and Chi-square tests.
Patients with downstaged IPSS-M had a median overall survival of 64 months, significantly higher than 22 months for unchanged/upstaged groups (p=0.0001).
Median relapse-free survival was 60 months for downstaged versus 6 months for others (p=0.0002).
Dynamic risk assessment showed significant differences in patient karyotypes and clinical outcomes between risk groups.